Can't find what you're looking for?

Try these pages:

Can testosterone prevent type 2 diabetes in men?

Losing weight reduces the risk of diabetes, and increases natural testosterone levels but it is not clear how much low testosterone influences the development of diabetes in overweight men. The testosterone for diabetes mellitus (T4DM) study looks at whether treatment with testosterone along with a weight management program prevents Type 2 diabetes in men at high risk, or reverses it in men newly diagnosed.

Posted in News

Can heavy drinking increase the risk of aggressive prostate cancer later in life?

Heavy consumption of alchohol is linked to a range of cancers, but it has been unclear whether heavy drinking increases the risk of prostate cancer. A recent study found that heavy drinking itself did not increase the odds but when a prostate cancer diagnosis was received, the grade of the cancer was significantly higher compared with men who drank less during their lifetime.

Posted in News

An investigation on the long-term health consequences of steroid use

Androgenic steroid use is rising and is now a major health concern, particularly for young men. Serious side effects include heart disease, brain and liver injury, infertility and other conditions. A large recent study investigating male gym-users who had used androgens showed a significant increase in the risk of death and other health conditions in these men.

Posted in News

Could the risk of erectile dysfunction be in your genes?

It's likely that some cases of erectile dysfunction are caused partly by genetics but until recently, no single gene had been found for a genetic link. Now researchers think they may have found a gene that is linked with the risk of erectile function in later life which may help to understand the cause of erectile dysfunction in some men, and lead to new treatments.

Posted in News

Immunotherapy hope for patients with advanced prostate cancer

Immunotherapy is a new treatment for aggressive cancers but for prostate cancer the success in clinical trials is mixed.The ability to pre-select which prostate cancer patients are likely to respond to immunotherapy, and which are unlikely to benefit, would be a major advance. Researchers have now found that a particular subgroup of prostate cancers have a distinct genetic identity and tumour immune microenvironment that may respond well to immunotherapy.

Posted in News